Sugi Predict

Sugi Predict / Targets / SLC8A1

SLC8A1

Sodium/calcium exchanger 1 · P32418 · SLC8A1 on Sugi Atlas →

3,266 patent compounds predicted against SLC8A1, 1,306 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL14759094 SCHEMBL14759094 1.00 20/20
SCHEMBL14759099 SCHEMBL14759099 1.00 20/20
SCHEMBL14759100 SCHEMBL14759100 1.00 20/20
SCHEMBL14759104 SCHEMBL14759104 1.00 20/20
SCHEMBL14759106 SCHEMBL14759106 1.00 20/20
SCHEMBL14759122 SCHEMBL14759122 1.00 20/20
SCHEMBL14759124 SCHEMBL14759124 1.00 20/20
SCHEMBL14759127 SCHEMBL14759127 1.00 20/20
SCHEMBL14759128 SCHEMBL14759128 1.00 20/20
SCHEMBL14759129 SCHEMBL14759129 1.00 20/20
SCHEMBL14759130 SCHEMBL14759130 1.00 20/20
SCHEMBL14759132 SCHEMBL14759132 1.00 20/20
SCHEMBL14759133 SCHEMBL14759133 1.00 20/20
SCHEMBL14759134 SCHEMBL14759134 1.00 20/20
SCHEMBL14759135 SCHEMBL14759135 1.00 20/20
SCHEMBL14759138 SCHEMBL14759138 1.00 20/20
SCHEMBL14759140 SCHEMBL14759140 1.00 20/20
SCHEMBL14759141 SCHEMBL14759141 1.00 20/20
SCHEMBL14759142 SCHEMBL14759142 1.00 20/20
SCHEMBL14759145 SCHEMBL14759145 1.00 20/20

Clinical trials — most relevant to SLC8A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma PHASE4COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops PHASE2UNKNOWN
Prevalence and Risk Factors of Nephrocalcinosis in Children at Sohag University Hospital nanUNKNOWN
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Lithium Countertransport and Blood Pressure In CARDIA and TOMHS nanCOMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Cardiovascular Effects of Empagliflozine nanUNKNOWN
Pharmacogenetics and Cardiovascular Events nanCOMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED
Sodium Transport: Genetics and Hypertension nanCOMPLETED
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS nanNOT_YET_RECRUITING
Genetic and Environmental Determinants of Hypertension nanCOMPLETED
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes nanRECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Identifying Diuretic Resistance in Patients With Acute Heart Failure nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Genetic Epidemiology of Blood Pressure Intervention nanCOMPLETED
When the Kidney Reacts to Nutritional Changes nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Calcitonin for Treating X-linked Hypophosphatemia nanCOMPLETED
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency nanRECRUITING
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management nanUNKNOWN
SLC13A5 Deficiency Natural History Study - Remote Only nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a SLC8A1 binder may also engage these)

ProteinNameSimilarity
P48765 — 1.000 P48765 →
Q01728 — 1.000 Q01728 →
P23685 — 1.000 P23685 →
P70414 — 1.000 P70414 →
P48767 — 1.000 P48767 →
S4R2P9 — 1.000 S4R2P9 →
P48766 — 1.000 P48766 →
P57103 — 1.000 P57103 →
P70549 — 1.000 P70549 →
Q8K596 — 1.000 Q8K596 →
Q9VDG5 — 0.995 Q9VDG5 →
P48768 — 0.993 P48768 →
P34322 — 0.991 P34322 →
Q9UPR5 — 0.990 Q9UPR5 →
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase 0.990 landscape →
A1ZAJ2 — 0.990 A1ZAJ2 →
Q1W675 — 0.990 Q1W675 →
Q8N3C0 — 0.989 Q8N3C0 →
Q9H1H9 — 0.988 Q9H1H9 →
Q03603 — 0.988 Q03603 →
Q7YZT6 — 0.988 Q7YZT6 →
B2MZD0 — 0.988 B2MZD0 →
P34410 — 0.988 P34410 →
Q9SJT7 — 0.988 Q9SJT7 →
Q9SCX5 — 0.988 Q9SCX5 →
Q80TN5 — 0.988 Q80TN5 →
Q29512 — 0.988 Q29512 →
A8WRG3 — 0.988 A8WRG3 →
Q99271 — 0.987 Q99271 →
Q19127 — 0.987 Q19127 →